Day: November 25, 2024

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Oslo, 25 November 2024: Reference is made to the stock exchange announcement published by Vow ASA (the “Company“) on 19 November 2024 regarding the approval by the extraordinary general meeting of the Company of a fully underwritten rights issue of 166,666,666 new shares in the Company, at a subscription price of NOK 1.50 per share (the “Rights Issue“). Reference...

Equinor ASA (OSE: EQNR, NYSE: EQNR) announced on 24 July 2024 an ordinary cash dividend per share of USD 0.35 and an extraordinary cash dividend per share of USD 0.35 for second quarter 2024. The NOK cash dividend per share is based on average USDNOK fixing rate from Norges Bank in the period plus/minus three business days from record date 19 November 2024, in total seven business days. Average Norges Bank fixing rate for this period was 11.0741. Total cash dividend for second quarter 2024 of USD 0.70 per share is consequently NOK 7.7519 per share. On 29 November 2024, the cash dividend will be paid to relevant shareholders on Oslo Børs (Oslo Stock Exchange) and to holders of American Depositary Receipts (“ADRs”) on New York Stock Exchange. This information is published in accordance with the requirements of the Continuing...

Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week dataLate-breaking Kisqali®* 4-year analysis on distant disease-free survival in key subgroups with HR+/HER2- early breast cancer from Phase III NATALEE trial also to be presentedPipeline updates demonstrate advancement in research and development programs in hematologic diseases and cancers  Basel, November 25, 2024 – Novartis will present data from more than 65 abstracts, including investigator-initiated trials at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition and the 2024 San Antonio Breast Cancer Symposium® (SABCS). “By prioritizing research in areas of greatest medical need and focusing on earlier stages of disease, we aim to change the...

Press Release Atos receives non-binding offer from the French State to acquire its Advanced Computing activities for an enterprise value of €500 million and up to €625 million including earn-outs Exclusive negotiations with the French State for the potential acquisition of 100% of BDS’s Advanced Computing activitiesProposed enterprise value of €500 million and up to €625 million including earn-outs Previous non-binding offer sent by the French State was on a wider perimeter including Mission Critical System and Cybersecurity Products businesses, in addition to the Advanced Computing business Exclusivity granted until May 31, 2025 Target to sign a Share Purchase Agreement by May 31, 2025 upon reception of customary commercial, employee and administrative authorizations Initial payment of €150 million to be made available upon signing...

Perth, Nov. 25, 2024 (GLOBE NEWSWIRE) — ANNUAL GENERAL MEETING RESULTS Perseus Mining Limited (ASX/TSX: PRU) (Perseus) wishes to release the results of its Annual General Meeting, held on 22 November 2024 at 3pm AWST. All six resolutions were decided on a poll and passed. In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act, details are set out on the next page.ASX/TSX CODE: PRU REGISTERED OFFICE: Level 2437 Roberts RoadSubiaco WA 6008 Telephone: +61 8 6144 1700Email: IR@perseusmining.com ABN: 27 106 808 986 WWW.PERSEUSMINING.COM CONTACTS: Jeff Quartermaine Managing Director & CEOjeff.quartermaine@perseusmining.com Nathan Ryan Media Relations+61 4 20 582 887nathan.ryan@nwrcommunications.com.auThis announcement was approved for release by Jeff Quartermaine, Managing Director and CEO.

Webcast planned for Monday, November 25th at 8:00 AM ET AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time.   Event Details:   Date: Monday, November 25thTime: 8:00 a.m. Eastern TimeWebcast: https://lifescievents.com/event/cassava/   A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences website for 90 days following the webcast. About Cassava Sciences, Inc. Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative...